{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:17:56Z","timestamp":1771237076278,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,12,25]],"date-time":"2014-12-25T00:00:00Z","timestamp":1419465600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s00347-014-3097-x","type":"journal-article","created":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T13:06:02Z","timestamp":1419339962000},"page":"127-139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Originalpr\u00e4parat versus Generika \u2013 Latanoprost","Original preparations versus generics \u2013 Latanoprost"],"prefix":"10.1007","volume":"112","author":[{"given":"M.A.","family":"Leitritz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-P.","family":"Lipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Voykov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,25]]},"reference":[{"key":"3097_CR1","unstructured":"Agency EM (2010) Guideline on the investigation of bioequivalence. In: Agency EM (Hrsg). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf"},{"key":"3097_CR2","unstructured":"Agency EM (1995) Note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents. European Medicines Agency. http:\/\/ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003687.pdf, S\u00a04"},{"key":"3097_CR3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5301\/ejo.5000041","volume":"22","author":"Allaire","year":"2012","unstructured":"Allaire C, Dietrich A, Allmeier H et al (2012) Latanoprost 0.005\u2009% test formulation is as effective as Xalatan\u00ae in patients with ocular hypertension and primary open-angle glaucoma. Eur J Ophthalmol 22:19\u201327","journal-title":"Eur J Ophthalmol"},{"key":"3097_CR4","doi-asserted-by":"crossref","first-page":"e002923","DOI":"10.1136\/bmjopen-2013-002923","volume":"3","author":"Almuzaini","year":"2013","unstructured":"Almuzaini T, Choonara I, Sammons H (2013) Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open 3:e002923","journal-title":"BMJ Open"},{"key":"3097_CR5","unstructured":"Roche.de (2013) Informationen f\u00fcr Patienten: Aussehen der Roche-Fertigspritze Pegasys. Roche Deutschland Holding GmbH. http:\/\/www.roche.de\/presse\/meldungen\/Informationen-fuer-Patienten-Aussehen-der-Original-Fertigspritze-Pegasyssupsup-3464. html?sid=01e4b1cedbb57fc42687f171747b77d3&bereich=Alle"},{"key":"3097_CR6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-2007-962834","volume":"224","author":"Bernauer","year":"2007","unstructured":"Bernauer W, Thiel MA, Rentsch KM (2007) Phosphate concentrations in antiglaucoma medication. Klin Monatsbl Augenheilkd 224:249\u2013251","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"3097_CR7","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/S0149-2918(03)80157-1","volume":"25","author":"Borgheini","year":"2003","unstructured":"Borgheini G (2003) The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 25:1578\u20131592","journal-title":"Clin Ther"},{"key":"3097_CR8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00347-012-2651-7","volume":"109","author":"Briesen","year":"2012","unstructured":"Briesen S, Guthoff R, Kilangalanga N et al (2012) Counterfeiting of eye drops? A laboratory study of antibiotic eye drops purchased in two African countries. Ophthalmologe 109:1207\u20131210","journal-title":"Ophthalmologe"},{"key":"3097_CR9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00061198-199710000-00011","volume":"6","author":"Cantor","year":"1997","unstructured":"Cantor LB (1997) Ophthalmic generic drug approval process: implications for efficacy and safety. J Glaucoma 6:344\u2013349","journal-title":"J Glaucoma"},{"key":"3097_CR10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.ophtha.2012.03.033","volume":"119","author":"Chambers","year":"2012","unstructured":"Chambers WA (2012) Ophthalmic generics \u2013 are they really the same? Ophthalmology 119:1095\u20131096","journal-title":"Ophthalmology"},{"key":"3097_CR11","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.ophtha.2013.01.002","volume":"120","author":"Chang","year":"2013","unstructured":"Chang DS, Friedman DS, Frazier T et al (2013) Development and validation of a predictive model for nonadherence with once-daily glaucoma medications. Ophthalmology 120:1396\u20131402","journal-title":"Ophthalmology"},{"key":"3097_CR12","unstructured":"Commission E (2009) Guideline on the readability of the label and package leaflet of medicinal products for human use. Revision 1, S\u00a027. http:\/\/ec.europa.eu\/health\/files\/eudralex\/vol-2\/c\/2009_01_12_readability_guideline_final_en.pdf"},{"key":"3097_CR13","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1007\/s00216-013-6811-7","volume":"405","author":"Desbenoit","year":"2013","unstructured":"Desbenoit N, Schmitz-Afonso I, Baudouin C et al (2013) Localisation and quantification of benzalkonium chloride in eye tissue by TOF-SIMS imaging and liquid chromatography mass spectrometry. Anal Bioanal Chem 405:4039\u20134049","journal-title":"Anal Bioanal Chem"},{"key":"3097_CR14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF01007833","volume":"235","author":"Diestelhorst","year":"1997","unstructured":"Diestelhorst M, Roters S, Krieglstein GK (1997) The effect of latanoprost 0.005\u2009% once daily versus 0.0015\u2009% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5\u2009%. Graefes Arch Clin Exp Ophthalmol 235:20\u201326","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3097_CR15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/BF02850204","volume":"23","author":"Friedlaender","year":"2006","unstructured":"Friedlaender MH, Breshears D, Amoozgar B et al (2006) The dilution of benzalkonium chloride (BAK) in the tear film. Adv Ther 23:835\u2013841","journal-title":"Adv Ther"},{"key":"3097_CR16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/OPTH.S40147","volume":"7","author":"Fukuda","year":"2013","unstructured":"Fukuda M, Shibata S, Shibata N et al (2013) Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations. Clin Ophthalmol 7:515\u2013520","journal-title":"Clin Ophthalmol"},{"key":"3097_CR17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11606-007-0470-3","volume":"23","author":"Goff","year":"2008","unstructured":"Goff SL, Mazor KM, Meterko V et al (2008) Patients\u2018 beliefs and preferences regarding doctors\u2018 medication recommendations. J Gen Intern Med 23:236\u2013241","journal-title":"J Gen Intern Med"},{"key":"3097_CR18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/IJG.0b013e3181f3eb4a","volume":"20","author":"Hermann","year":"2011","unstructured":"Hermann MM, Bron AM, Creuzot-Garcher CP et al (2011) Measurement of adherence to brimonidine therapy for glaucoma using electronic monitoring. J Glaucoma 20:502\u2013508","journal-title":"J Glaucoma"},{"key":"3097_CR19","unstructured":"Inc P (1996) Xalatan Produkt-Monography. Prostaglandin F2\u03b1 analogue. Control No. 158286 FDA Zulassungsunterlagen NDA 20-597"},{"key":"3097_CR20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/jop.2010.0115","volume":"27","author":"Johnson","year":"2011","unstructured":"Johnson TV, Gupta PK, Vudathala DK et al (2011) Thermal stability of bimatoprost, latanoprost, and travoprost under simulated daily use. J Ocul Pharmacol Ther 27:51\u201359","journal-title":"J Ocul Pharmacol Ther"},{"key":"3097_CR21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/02713683.2011.631722","volume":"37","author":"Kahook","year":"2012","unstructured":"Kahook MY, Fechtner RD, Katz LJ et al (2012) A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry. Curr Eye Res 37:101\u2013108","journal-title":"Curr Eye Res"},{"key":"3097_CR22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1081\/DDC-120003445","volume":"28","author":"Kaur","year":"2002","unstructured":"Kaur IP, Kanwar M (2002) Ocular preparations: the formulation approach. Drug Dev Ind Pharm 28:473\u2013493","journal-title":"Drug Dev Ind Pharm"},{"key":"3097_CR23","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1001\/jama.2008.758","volume":"300","author":"Kesselheim","year":"2008","unstructured":"Kesselheim AS, Misono AS, Lee JL et al (2008) Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 300:2514\u20132526","journal-title":"JAMA"},{"key":"3097_CR24","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/S0140-6736(04)16538-0","volume":"363","author":"Khan","year":"2004","unstructured":"Khan A (2004) WHO drops two generics from approved HIV drugs list. Lancet 363:2147","journal-title":"Lancet"},{"key":"3097_CR25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3341\/kjo.2013.27.6.446","volume":"27","author":"Kim","year":"2013","unstructured":"Kim EJ, Kim YH, Kang SH et al (2013) In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells. Korean J Ophthalmol 27:446\u2013453","journal-title":"Korean J Ophthalmol"},{"key":"3097_CR26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/ICU.0b013e32831d1fc7","volume":"20","author":"Law","year":"2009","unstructured":"Law SK (2009) Switching within glaucoma medication class. Curr Opin Ophthalmol 20:110\u2013115","journal-title":"Curr Opin Ophthalmol"},{"key":"3097_CR27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jcjo.2011.12.004","volume":"47","author":"Mammo","year":"2012","unstructured":"Mammo ZN, Flanagan JG, James DF et al (2012) Generic versus brand-name North American topical glaucoma drops. Can J Ophthalmol 47:55\u201361","journal-title":"Can J Ophthalmol"},{"key":"3097_CR28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.transproceed.2003.11.008","volume":"36","author":"Masri","year":"2004","unstructured":"Masri MA, Andrysek T, Rizk S et al (2004) The role of generics in transplantation: TM-MMF versus Cellcept in healthy volunteers. Transplant Proc 36:84\u201385","journal-title":"Transplant Proc"},{"key":"3097_CR29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00061198-200110000-00007","volume":"10","author":"Morgan","year":"2001","unstructured":"Morgan PV, Proniuk S, Blanchard J et al (2001) Effect of temperature and light on the stability of latanoprost and its clinical relevance. J Glaucoma 10:401\u2013405","journal-title":"J Glaucoma"},{"key":"3097_CR30","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1167\/iovs.12-10766","volume":"53","author":"Pauly","year":"2012","unstructured":"Pauly A, Roubeix C, Liang H et al (2012) In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation. Invest Ophthalmol Vis Sci 53:8172\u20138180","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3097_CR31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000192082","volume":"41","author":"Pellinen","year":"2009","unstructured":"Pellinen P, Lokkila J (2009) Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Ophthalmic Res 41:118\u2013122","journal-title":"Ophthalmic Res"},{"key":"3097_CR32","unstructured":"Products TEaFTEOMP-CFPOM (2001) Note for guidance on the investigation of bioavailability and bioequivalence. In: Products TEAftEoMP-CfPoM (Hrsg). http:\/\/www.ema.europe.eu"},{"key":"3097_CR33","unstructured":"Progenerika_E.V. (2013) http:\/\/www.progenerika.de\/downloads\/10408\/Marktdaten2012"},{"key":"3097_CR34","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00347-002-0613-1","volume":"99","author":"Schlote","year":"2002","unstructured":"Schlote T (2002) Side-effects and risk profile of latanoprost 0.005\u2009% (Xalatan). Ophthalmologe 99:724\u2013729","journal-title":"Ophthalmologe"},{"key":"3097_CR35","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00063-006-1097-6","volume":"101","author":"Simmenroth-Nayda","year":"2006","unstructured":"Simmenroth-Nayda A, Hummers-Pradier E, Ledig T et al (2006) Prescription of generic drugs in general practice. Results of a survey of general practitioners. Med Klin 101:705\u2013710","journal-title":"Med Klin"},{"key":"3097_CR36","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0039-6257(02)00302-8","volume":"47","author":"Sjoquist","year":"2002","unstructured":"Sjoquist B, Stjernschantz J (2002) Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 47(Suppl 1):S6\u2013S12","journal-title":"Surv Ophthalmol"},{"key":"3097_CR37","doi-asserted-by":"crossref","unstructured":"Takada Y, Okada Y, Fujita N et al (2012) A patient with corneal epithelial disorder that developed after administration of a latanoprost generic, but not a brand-name drug, eye drop. Case Rep Ophthalmol Med. doi: 10.1155\/2012\/536746","DOI":"10.1155\/2012\/536746"},{"key":"3097_CR38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.survophthal.2003.12.009","volume":"49","author":"Van","year":"2004","unstructured":"Van Santvliet L, Ludwig A (2004) Determinants of eye drop size. Surv Ophthalmol 49:197\u2013213","journal-title":"Surv Ophthalmol"},{"key":"3097_CR39","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1089\/jop.2013.0002","volume":"29","author":"Xu","year":"2013","unstructured":"Xu M, Sivak JG, Mccanna DJ (2013) Comparison of the effects of ophthalmic solutions on human corneal epithelial cells using fluorescent dyes. J Ocul Pharmacol Ther 29:794\u2013802","journal-title":"J Ocul Pharmacol Ther"},{"key":"3097_CR40","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/ICU.0b013e328089f1c8","volume":"18","author":"Yee","year":"2007","unstructured":"Yee RW (2007) The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol 18:134\u2013139","journal-title":"Curr Opin Ophthalmol"},{"key":"3097_CR41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1528-1167.2008.01703.x","volume":"50","author":"Zachry","year":"2009","unstructured":"Zachry WM III, Doan QD, Clewell JD et al (2009) Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 50:493\u2013500","journal-title":"Epilepsia"},{"key":"3097_CR42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bjophthalmol-2012-302245","volume":"97","author":"Zore","year":"2013","unstructured":"Zore M, Harris A, Tobe LA et al (2013) Generic medications in ophthalmology. Br J Ophthalmol 97:253\u2013257","journal-title":"Br J Ophthalmol"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-014-3097-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-014-3097-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-014-3097-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T21:35:53Z","timestamp":1650836153000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-014-3097-x"}},"subtitle":["Wie gleich ist unterschiedlich?","How similar is different?"],"short-title":[],"issued":{"date-parts":[[2014,12,25]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["3097"],"URL":"https:\/\/doi.org\/10.1007\/s00347-014-3097-x","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,25]]}}}